Canada Markets closed

Today's Research Reports on GeneNews, Medicure, Aphria and Resverlogix

NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

GeneNews Limited
https://rdinvesting.com/news/?ticker=GEN.TO

Medicure Inc.
https://rdinvesting.com/news/?ticker=MPH.V

Aphria Inc.
https://rdinvesting.com/news/?ticker=APH.TO

Resverlogix Corp.
https://rdinvesting.com/news/?ticker=RVX.TO

GeneNews’ stock had no change Wednesday, to close the day at $0.045. The stock recorded a trading volume of 127,000 shares, which was above its three months average volume of 114,384 shares. In the last year, GeneNews' shares have traded in a range of 0.05 - 0.24. The share price has fallen 0% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.058 is lower than its 200-day moving average of $0.074. Shares of GeneNews have fallen approximately 78.26 percent year-to-date.

Access RDI's GeneNews Limited Research Report at:
https://rdinvesting.com/news/?ticker=GEN.TO

On Wednesday, shares of Medicure recorded a trading volume of 3,729 shares, which was above the three months average volume of 3,498 shares. The stock ended the day 1.3% lower at $6.85. The share price has fallen 21.71% from its 52 week high with a 52 week trading range of 5.56 - 8.75. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $6.97 is greater than its 200-day moving average of $6.88. Shares of the company are trading at a Price to Earnings ratio of 2.47. Shares of Medicure have fallen approximately 8.05 percent year-to-date.

Access RDI's Medicure Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MPH.V

Aphria’s stock jumped 17.96% Wednesday, to close the day at $15.70. The stock recorded a trading volume of 13,782,758 shares, which was above its three months average volume of 11,238,276 shares. In the last year, Aphria's shares have traded in a range of 7.51 - 24.75. The share price has gained 109.05% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $18.07 is greater than its 200-day moving average of $13.52. Shares of the company are trading at a Price to Earnings ratio of 87.22. Shares of Aphria have fallen approximately 16.04 percent year-to-date.

Access RDI's Aphria Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APH.TO

On Wednesday, shares of Resverlogix recorded a trading volume of 74,770 shares, which was below the three months average volume of 108,696 shares. The stock ended the day 1.83% higher at $3.33. The share price has fallen 22.74% from its 52 week high with a 52 week trading range of 1.11 - 4.31. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.35 is greater than its 200-day moving average of $2.49. Shares of Resverlogix have gained approximately 62.44 percent year-to-date.

Access RDI's Resverlogix Corp. Research Report at:
https://rdinvesting.com/news/?ticker=RVX.TO

Our Actionable Research on GeneNews Limited (TSX : GEN.TO ), Medicure Inc. (TSXV : MPH.V ), Aphria Inc. (TSX : APH.TO ) and Resverlogix Corp. (TSX : RVX.TO ) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com